A5017227796- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Diet and metabolism studies
- Medical Imaging Techniques and Applications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Health and Disease Prevention
- Nutritional Studies and Diet
- Frailty in Older Adults
- Parkinson's Disease Mechanisms and Treatments
- Blood Pressure and Hypertension Studies
- Functional Brain Connectivity Studies
- Neurological Disease Mechanisms and Treatments
Sungkyunkwan University
2023-2025
Samsung Medical Center
2023-2025
Samsung (South Korea)
2025
Seoul National University Hospital
2024
Importance Understanding the characteristics of discordance between plasma biomarkers and positron emission tomography (PET) results in Alzheimer disease (AD) is crucial for accurate interpretation findings. Objective To compare (1) medical comorbidities affecting biomarker concentrations, (2) imaging clinical features, (3) cognitive changes PET discordant concordant cases. Design, Setting, Participants This multicenter cohort study, conducted 2016 2023, included individuals with unimpaired...
Physical activity (PA) is a nonpharmacological intervention for dementia prevention. The association between PA and Alzheimer disease (AD) plasma biomarkers remains underexplored. To investigate the associations among PA; biomarkers, including β-amyloid 42/40 (Aβ42/40), phosphorylated-tau217 (ptau217), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL); cognition. This cross-sectional study included participants with without cognitive impairment recruited from multiple...
Abstract Background Risk factors for cardiovascular disease, including elevated blood pressure, are known to increase risk of Alzheimer’s disease. There has been increasing awareness the relationship between long-term pressure (BP) patterns and their effects on brain. We aimed investigate association repeated BP measurements with vascular disease markers. Methods recruited 1,952 participants without dementia August 2015 February 2022. During serial clinic visits, we assessed both systolic...
Abstract INTRODUCTION We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans non‐Hispanic Whites (NHWs). METHODS included 5121 from multiple centers across South Korea 929 NHWs Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants underwent Aβ positron emission tomography were categorized into cognitively unimpaired (CU), mild impairment (MCI), dementia stages. Age, sex, education, apolipoprotein E . genotype adjusted using...
Abstract Background Tau‐PET imaging allows in‐vivo detection of neurofibrillary tangles. One tau‐PET tracer (i.e., [ 18 F]flortaucipir) has received FDA‐approval for clinical use, and multiple other tracers have been implemented into trials participant selection and/or as a primary or secondary outcome measure. To optimize future use tau‐PET, it is essential to understand how demographic, genetic factors affect tau‐PET‐positivity rates. Method This large‐scale multi‐center study includes...
Background The clinical effects of β-amyloid positivity (Aβ+) on copathologies in various dementias remain relatively underexamined. Thus, the present study was conducted to investigate prevalence and Aβ+ subcortical vascular cognitive impairment (SVCI) frontotemporal dementia (FTD). Patients Methods We enrolled SVCI (n = 583), FTD 152), cognitively unimpaired (CU) participants 1,249) who underwent Aβ PET scans. odds having were subsequently compared among diagnostic groups (CU, SVCI, FTD)...
Abstract Background Ethnic differences in amyloid‐β (Aβ) characteristics and cognitive trajectories should be considered, when designing Aβ‐targeted therapies. The clinical effects of co‐pathologies Aβ have not been evaluated extensively across various dementias. We investigated the prevalence Aβ+ Koreans non‐Hispanic whites (NHWs) with Alzheimer’s syndrome (ACS) other Method included 5,856 who underwent positron emission tomography (PET) South Korea. participants were categorized into...
Abstract Background Tau‐PET imaging allows in‐vivo detection of neurofibrillary tangles. One tau‐PET tracer (i.e., [18F]flortaucipir) has received FDA‐approval for clinical use, and multiple other tracers have been implemented into trials participant selection and/or as a primary or secondary outcome measure. To optimize future use tau‐PET, it is essential to understand how demographic, genetic factors affect tau‐PET‐positivity rates. Method This large‐scale multi‐center study includes 9713...